Insilico Medicine and Eli Lilly agreed to a commercialization deal worth up to $2.75 billion in biobucks, including $115 million upfront, covering certain preclinical AI-discovered oral candidates. The arrangement gives Lilly rights to develop, manufacture, and commercialize some of Insilico’s candidates in specified disease areas. The deal underscores how pharmaceutical incumbents are increasingly using AI discovery portfolios as a sourcing channel for preclinical assets—then monetizing through milestone-linked commercial rights. It also reflects the growing importance of oral delivery strategies for GLP-1 and other high-volume chronic indications. The next milestone focus will be which specific molecules Lilly licensed and how quickly the parties advance them into clinical development, particularly as the sector intensifies competition for next-generation therapeutic formats.